Merus N.V. (MRUS)
NASDAQ: MRUS · Real-Time Price · USD
42.93
-0.56 (-1.29%)
At close: Nov 20, 2024, 4:00 PM
43.00
+0.07 (0.16%)
After-hours: Nov 20, 2024, 6:27 PM EST
Merus Revenue
Merus had revenue of $11.77M in the quarter ending September 30, 2024, with 6.70% growth. This brings the company's revenue in the last twelve months to $35.93M, down -21.33% year-over-year. In the year 2023, Merus had annual revenue of $43.95M with 5.68% growth.
Revenue (ttm)
$35.93M
Revenue Growth
-21.33%
P/S Ratio
73.50
Revenue / Employee
$156,908
Employees
229
Market Cap
2.94B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 43.95M | 2.36M | 5.68% |
Dec 31, 2022 | 41.59M | -7.52M | -15.32% |
Dec 31, 2021 | 49.11M | 19.16M | 64.00% |
Dec 31, 2020 | 29.94M | -1.19M | -3.82% |
Dec 31, 2019 | 31.13M | -7.25M | -18.88% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Bausch Health Companies | 9.47B |
Surgery Partners | 2.99B |
Amedisys | 2.32B |
Inari Medical | 574.50M |
Amicus Therapeutics | 493.67M |
Veracyte | 425.33M |
MRUS News
- 14 days ago - Merus to Present at Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - Merus: Petosemtamab Set Up For December 2024 Data Presentation - Seeking Alpha
- 16 days ago - Merus Receives FDA extension of PDUFA for zenocutuzumab - GlobeNewsWire
- 21 days ago - Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update - GlobeNewsWire
- 3 months ago - Merus: Great European Oncology Developer, But Properly Valued - Seeking Alpha
- 3 months ago - Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update - GlobeNewsWire
- 4 months ago - Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC - GlobeNewsWire
- 6 months ago - Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting - GlobeNewsWire